Indoco Remedies Ltd. Results Earnings Call for Q4FY23
Conference Call with Indoco Remedies Ltd. Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.23-05-2023
23-05-2023
INDOCO REMEDIES LTD. - 532612 - Intimation Of Re- Appointment Of Mr. Suresh G. Kare As Chairman Of The Company In The Capacity Of Non-Executive Non Independent Director
As per the provisions of Regulation 30 and Part-A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of the Directors of the Company at their meeting held today i.e. 23rd May, 2023 took note of completion of term of Mr. Suresh G Kare (DIN 00179220) as Chairman and Wholetime Director w.e.f. 30th June, 2023 and re-appointed Mr. Suresh G. Kare as Chairman of the Company in the capacity of Non-Executive Non Independent Director with effect from 01st July, 2023, subject to the approval of shareholders.23-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Indoco Remedies Ltd.
Pharmaceuticals company Indoco Remedies announced Q4FY23 & FY23 results: Q4FY23: During Q4FY23, revenues grew by 6.9% at Rs 428.0 crore, as against Rs 400.3 crore in Q4FY22 EBIDTA to net sales for Q4FY23 is 15.0% at Rs 64.2 crore, compared to 20.1% at Rs 80.5 crore in Q4FY22 For Q4FY23, the Profit After Tax is at Rs 25.4 crore, compared to Rs 40.4 crore in Q4FY22 Profit After Tax with other comprehensive income is at Rs 29.7 crore, compared to Rs 35.6 crore in Q4FY22 FY23: For FY23, the revenues grew by 9.0% at Rs 1,638.1 crore, as against Rs 1,502.7 crore in FY22 EBIDTA to net sales for FY23 is 17.4% at Rs 284.9 crore, compared to 21.8% at Rs 327.0 crore in FY22 For FY23, the Profit After Tax is at Rs 141.4 crore, compared to Rs 154.5 crore in FY22 Profit After Tax with other comprehensive income is at Rs 142.8 crore, compared to Rs 149.2 crore in FY22 Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “Our performance this year is a function of a predictable performance of India business, free of COVID impact, accompanied by a good performance of Export business”. Result PDF23-05-2023
INDOCO REMEDIES LTD. - 532612 - Financial Results For The Quarter And Year Ended 31St March 2023
Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 23rd May, 2023 has considered and approved the Audited Financial Results (Consolidated and Standalone) for the quarter and year ended 31st March, 2023 and Auditors' Reports with unmodified opinions on the aforesaid Audited Financial Results.23-05-2023
INDOCO REMEDIES LTD. - 532612 - Board Meeting Outcome for Outcome Of Board Meeting Held On 23Rd May, 2023
Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 23rd May, 2023 has inter-alia considered and approved the following. 1. Audited Financial Results (Consolidated and Standalone) for the quarter and year ended 31st March, 2023 and Auditors' Reports with unmodified opinions on the aforesaid Audited Financial Results. 2. Subject to the approval of the Members at the ensuing 76th Annual General Meeting, recommended a Dividend of Rs. 2.25 per equity share on face value of Rs. 2/- for the financial year 2022-2023.23-05-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Earnings Conference Call on Audited Financial Results for fourth quarter and year ended 31st March, 202315-05-2023
INDOCO REMEDIES LTD. - 532612 - Board Meeting Intimation for Audited Results (Standalone And Consolidated) For The Quarter And Year Ended 2022-23 & Dividend For The Year Ended 2022-23
INDOCO REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 ,inter alia, to consider and approve 1. To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March, 2023. 2. To Recommend a final dividend, if any for the financial year ending 31st March, 2023.12-05-2023
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Further to the intimation dated January 23, 2023, on the audit conducted by the United States Food and Drug Administration (USFDA) at our Solid Oral Formulation Facility (Plant 1) at Goa, from January 16, 2023 to January 20, 2023, the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection. Please find enclosed herewith press release in this regard. Kindly take the above information on record.03-05-2023